Most Read Articles
Pearl Toh, 2 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Electrical nerve stimulation helps mitigate movement-evoked pain in fibromyalgia

12 Jan 2020

Use of active transcutaneous electrical nerve stimulation (TENS) in fibromyalgia (FM) patients receiving treatment results in a favourable reduction in movement-evoked pain, according to the results of a trial.

The trial randomized female FM patients receiving steady medication to active TENS (n=103), placebo TENS (n=99) or no TENS (n=99). TENS was applied to the lumbar and cervicothoracic regions using a modulated frequency (2–125Hz) at the highest tolerable intensity, with patients instructed to use it at home 2h/day during activity for 4 weeks.

Movement‐evoked pain (primary outcome) and fatigue were rated on an 11‐point scale before and during application of TENS.

After 4 weeks, movement-evoked pain decreased significantly with active TENS vs placebo TENS (mean difference, –1.0, 95 percent confidence interval [CI], –1.8 to –0.2; p=0.008) and no TENS (mean difference, –1.8, 95 percent CI, –2.6 to –1.0; p<0.0001). The same was observed for fatigue (mean difference, –1.4, 95 percent CI, –2.4 to –0.4; p=0.001 and mean difference, –1.9, 95 percent CI, –2.9 to –0.9; p=0.0001, respectively).

Significantly more patients in the active‐TENS group reported improvement in the global impression of change than in the placebo‐TENS and no-TENS groups (70 percent vs 31 percent and 9 percent, respectively; p-both<0.0001).

There were no reports of TENS‐related serious adverse events, with <5 percent of the overall population experiencing minor adverse events with TENS.

Additional investigation is warranted to examine effectiveness in a real world, pragmatic setting to establish clinical importance of the present data, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 2 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 4 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.